Related Experiment Video
Updated: Aug 24, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Gefitinib for advanced or metastatic non-small cell lung cancer
Abstract:
Gefitinib is approved as monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have failed prior platinum-based treatment and docetaxel chemotherapy. Its efficacy when compared to standard treatment and best supportive care is unproven. Common drug-related adverse effects include gastrointestinal and skin disorders. Rare but serious drug-related adverse events, such as shock, thrombophlebitis, thrombocytopenia and interstitial lung disease, have been reported.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers